قدِّم طلبك الآن 
الدكتور راميش الانجو
باحث ما بعد الدكتوراه
البريد الإلكتروني
relango@hbku.edu.qaالهاتف
55 166 846موقع المكتب
Segment-6,1st Floor, Building No: 2
الدكتور راميش الانجو
باحث ما بعد الدكتوراه
المؤهلات العلمية
PhD in Biochemistry
MSc in Biochemistry
الكيان
معهد قطر لبحوث الطب الحيوي
Divison
مركز البحوث التطبيقية للسرطان
السيرة الذاتية
Dr. Ramesh Elango is a Postdoctoral Researcher at Qatar Biomedical Research Institute’s Translational Oncology Research Center. He earned his PhD from Bharathidasan University, India, where he researched the anti-atherogenic effects of epigallocatechin gallate from green tea. His work demonstrated that EGCG protects against oxidative damage, reduces inflammation, and regulates key genes involved in cholesterol metabolism. Dr. Ramesh Elango is an expert in advanced techniques such as CRISPR/Cas9-based functional genomics, RNA sequencing, and the profiling of microRNAs and long noncoding RNAs (lncRNAs).
He later completed postdoctoral studies at King Saud University, Saudi Arabia, where his work led to the discovery of a miRNA-based molecular signature associated with lymph node metastasis in breast cancer. His research focuses on pioneering cancer therapies and identifying novel molecular biomarkers. With over a decade of experience in cancer research, his contributions have been pivotal in identifying therapeutic targets in aggressive cancer subtypes, particularly triple-negative breast cancer (TNBC). He emphasizes the translation of molecular discoveries into clinical applications. Dr. Elango has published over 30 peer-reviewed research articles and book chapters, contributing significantly to the field of oncology.
PhD in Biochemistry
Bharathidasan University, India
2009
MSc in Biochemistry
Periyar University, India
2003
BSc in Biochemistry
Periyar University, India
2001
- Exploring molecular signatures for predicting pathological complete response to Neoadjuvant therapy in breast cancer
- Utilizing transcriptomic profiling for insights into breast cancer diagnosis, prognosis, and therapeutic approaches
- Applying CRISPR-Cas9 genomic screens to uncover novel therapeutic vulnerabilities and mechanisms of chemotherapy resistance in breast cancer
- Investigating miRNA and lncRNA signatures in triple-negative breast cancer (TNBC) for understanding treatment resistance and tumorigenicity
Postdoctoral Researcher
Qatar Biomedical Research Institute, Hamad Bin Khalifa University
2019 - Present
Assistant Research Professor
Stem Cell Unit, King Saud University, Saudi Arabia
2016 - 2019
Biotechnology Application Specialist
Asila-Riyadh Company, Saudi Arabia
2012 - 2016
Postdoctoral Researcher
Food Science and Nutrition, King Saud University, Saudi Arabia
2009 - 2012
Elango, R., Vishnubalaji, R., Rashid, S., Al-Sarraf, R., Akhtar, M., Ouararhni, K., & Alajez, N. M. (2024). Long noncoding RNA profiling unveils LINC00960 as an unfavorable prognostic biomarker promoting triple-negative breast cancer progression. Cell Death Discovery, 10(1), 333.
Elango, R., Rashid, S., Vishnubalaji, R., Al-Sarraf, R., Akhtar, M., Ouararhni, K., Decock, J., Albagha, O. M. E., & Alajez, N. M. (2023). Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks. Cell Death & Disease, 14(1), 415.
Elango, R., Vishnubalaji, R., Shaath, H., & Alajez, N. M. (2021). Transcriptional alterations of protein-coding and noncoding RNAs in triple-negative breast cancer in response to DNA methyltransferases inhibition. Cancer Cell International.
Elango, R., Vishnubalaji, R., Shaath, H., & Alajez, N. M. (2021). Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel. Molecular Therapy - Methods & Clinical Development, 20, 601–614.
Elango, R., Alsaleh, K. A., Vishnubalaji, R., Manikandan, M., Ali, A. M., Abd El-Aziz, N., Altheyab, A., Al-Rikabi, A., Alfayez, M., Aldahmash, A., & Alajez, N. M. (2020). MicroRNA expression profiling on paired primary and lymph node metastatic breast cancer revealed a distinct microRNA profile associated with LNM. Frontiers in Oncology.